Price T Rowe Associates Inc Gilead Sciences, Inc. Transaction History
Price T Rowe Associates Inc
- $883 Billion
- Q2 2025
A detailed history of Price T Rowe Associates Inc transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 23,586,692 shares of GILD stock, worth $2.83 Billion. This represents 0.3% of its overall portfolio holdings.
Number of Shares
23,586,692
Previous 14,703,103
60.42%
Holding current value
$2.83 Billion
Previous $1.65 Billion
58.73%
% of portfolio
0.3%
Previous 0.2%
Shares
19 transactions
Others Institutions Holding GILD
# of Institutions
2,315Shares Held
992MCall Options Held
9.23MPut Options Held
9.49M-
Black Rock Inc. New York, NY121MShares$14.5 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA119MShares$14.3 Billion0.22% of portfolio
-
State Street Corp Boston, MA59.2MShares$7.1 Billion0.25% of portfolio
-
Capital World Investors Los Angeles, CA46.3MShares$5.56 Billion0.78% of portfolio
-
Wellington Management Group LLP Boston, MA37.5MShares$4.5 Billion0.79% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $150B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...